Cellens is commercializing an AI-based, cell-imaging platform for bladder cancer diagnostics. The platform leverages atomic force microscopy (AFM) imaging and machine learning modeling to perform a non-invasive test that quantifies physio-biomarkers on cell surfaces. By analyzing urine samples they can provide a diagnostic score for urologists. This ability to detect malignancy from as few as five to 10 cells reduces the need for invasive and costly procedures.